Medicines like the Ozempic and the Wegovy from the new Nordisk, and the MOUNJARO from Eli Lilly, they become increasingly popular due to their effects on weight loss. Initially approved for the treatment of type 2 diabetes the molecules present in this type of medicine, known as “weight loss pens”, are widely used to treat obesity.
The fame of these drugs is due to the way they act in the body: Semaglutide, an active ingredient of Ozempic and Wegovy, acts directly on insulin secretion by the pancreas, helping to regulate the level of blood glucose. In addition, the molecule helps to slow gastric emptying, promoting a greater sense of satiety.
Mounjaro, on the other hand, has as an active ingredient the tirzepatit. This molecule is of the same class as Semaglutado-the so-called GLP-1 agonists, a hormone produced by the gut. However, its differential is in a second performance: the molecule also acts on the GIP receiver, another hormone that plays an important role in regulating blood glucose and lipid metabolism.
In clinical trials, Wegovy led to an average reduction of 17% of weight, and one third of patients had a reduction exceeding 20%. In another recent study, Mounjaro promoted a relative weight loss 47% higher than its competitor.
But when the treatment is over, what happens? According to Tarissa Petry, endocrinologist at the Center Specialized in Obesity and Diabetes of the German Hospital Oswaldo Cruz, it is essential that both the indication of the use of these medicines and the weaning and the end of treatment are made with the accompaniment of a multidisciplinary team . This includes, in addition to endocrinologist, health professionals such as nutritional and psychologists, to avoid the dreaded “rebound effect”, ie the weight regank.
“These drugs act in intestinal hormones, that is, they act directly at the center of satiety. This makes the withdrawal [do remédio] be quieter, with a gradual decrease in doses, ”explains Petry to CNN . “If the patient is in multidisciplinary follow -up, with nutritionist, for example, he learns to better choose food and this process is important so that he does not feel that huge hunger when to medication, because he can, yes, return to old habits without this follow -up,” he says.
The expert also reinforces that Obesity is considered a chronic disease like Type 2 diabetes. Therefore, treatment and medical follow -up should be done throughout life, even after weight decrease and blood glucose regulation.
“It is important to emphasize that the guilt [por um possível efeito rebote] It is not from the person. It is the fault of the disease itself, ”he says, explaining that obesity has causal factors related to genetics.“ The mechanism of obesity causes the person to gain weight again. When the person loses weight, the body tries to fight this loss. It is a defense mechanism that science has not yet been able to change. And this happens through metabolism, which gets slower, and the hormone production that hungry, ”he explains.
To minimize the impact of the end of using this type of medicine, as well as nutritional and psychological follow -up – to address, when there is emotional issues such as dietary binge, for example – it is important to exercise.
“This is the basis for a healthy life for all, not only for those who have obesity. But for these patients, it is important that this process of lifestyle change is done with medication, so that the patient develops this discipline from the beginning [do tratamento]”He guides.
This content was originally published in Ozempic, Wegovy and Mounjaro: What can happen after weight loss? on the CNN Brazil website.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
